hrp0098p3-123 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2024

GLI2 variant associated with hypopituitarism and midline defects

Lia Magnacavallo Anna , Sterpetti Giulia , Polenzani Ilaria , Mascaro Rossella , Errico Angela , Bucolo Carmen , Laura Carla Meroni Silvia , Barera Graziano , Cinzia Pozzobon Gabriella

Pituitary stalk interruption syndrome (PSIS) can be classified as a form of holoprosencephaly. The sonic hedgehog signaling (SHH) has a key role in central nervous system midline development. GLI2 is a transcription factor of SHH pathway. GLI2 pathogenetic variants show phenotypic variability and nonpenetrance. We present a female patient born at 37+1 weeks of gestation from moroccans non-consanguineous parents. Unicogenic. Polihydramnios, urogenital sinus, palatal and lip cle...

hrp0098p3-220 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

Septo-optic dysplasia and panhypopituitarism: a case report

Lia Magnacavallo Anna , Sterpetti Giulia , Polenzani Ilaria , Mascaro Rossella , Errico Angela , Bucolo Carmen , Laura Carla Meroni Silvia , Barera Graziano , Cinzia Pozzobon Gabriella

Septo-optic dysplasia (SOD) is characterized by optic nerve hypoplasia, hypothalamic-pituitary axis dysfunction and brain’s midline structures defects. His clinical features are heterogeneous. They consist mainly in visual impairments, endocrine dysfunction, cognitive and neurological abnormalities. We present a patient of 6 years old, affected by SOD, central diabetes insipidus, central hypothyroidism and growth hormone deficiency (GHD). She was born at 40+2 gestational...

hrp0098p3-225 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

Management challenges in a pediatric somatotropinoma

Polenzani Ilaria , Errico Angela , Mascaro Rossella , Lia Magnacavallo Anna , Sterpetti Giulia , Laura Carla Meroni Silvia , Bucolo Carmen , Barera Graziano , Losa Marco , Pozzobon Gabriella

Female, 7-year-old, presented with a 6-months history of headaches and right ptosis, with a sudden worsening associated with projectile vomiting. Height 141 cm (2.67 SDS), weight 44.35 kg (1.98 SDS). She presented with enlarged hands and feet, diastema, broad nasal bridge, prominent nasal septum, low-set ears and coarse facial features. Brain MRI revealed a 22 × 25 × 40 mm pituitary mass with a suprasellar extension compressing the optic chiasm and invading the cav...

hrp0098p3-224 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

Delayed diagnosis of congenital hypopituitarism presenting as syndromic obesity

Polenzani Ilaria , Mascaro Rossella , Lia Magnacavallo Anna , Errico Angela , Sterpetti Giulia , Laura Carla Meroni Silvia , Bucolo Carmen , Barera Graziano , Pozzobon Gabriella

Male, aged 6 years 3 months, recently moved from Peru, was admitted for suspected syndromic obesity. His medical history was unremarkable; no documented neonatal hypoglycemia or prolonged jaundice. Independent walking was achieved at 3 years and meaningful words at 2. Physical examination: height 99.2 cm (-3.57 SDS), -2.8 SDS below target height, BMI 27.43 kg/m2 (2.47 SDS); his weight has increased since the age of 4. Peculiar somatic characteristics were observed - saddle nos...

hrp0092p1-98 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Final Height in Oncological Growth Hormone Deficient (GHD) Children After Growth Hormone (GH) Therapy

Rodari Giulia , Cattoni Alessandro , Albanese Assunta

Background: Growth hormone deficiency (GHD) is the commonest hypothalamic-pituitary (HP) disorder in cancer survivors. The only few studies in literature addressing GH efficacy in a large cohort of patients concluded that, though improving height outcome, GH therapy may not entirely restore final height (FH) potential according to mid-parental height (MPH). Thus, in order to optimize outcome, more information on factors influencing growth response in these chi...

hrp0082p3-d1-904 | Pituitary | ESPE2014

Long-Term Endocrinological Follow-Up in Diencephalic Syndrome

Parpagnoli Maria , Seminara Salvatore , Anzilotti Giulia

Background: Diencephalic syndrome (DS), diencephalic cachexia or Russell syndrome, is a rare, rapidly fatal condition, usually occurring during the first year of life, as a result of a hypothalamic dysfunction due to hypothalamic/chiasmatic tumors. Clinical features of DS are weight loss leading to cachexia despite a normal caloric intake and growth rate, hyperalertness, hyperkinesis, and euphoria. Treatment is related to treatment of the hypothalamic lesion. The role of cytok...

hrp0082p3-d1-934 | Puberty and Neuroendocrinology | ESPE2014

An Unusual Combination of Premature Ovarian Failure and a History of GNRH Treatment for Idiopathic Precocious Puberty

Parpagnoli Maria , Seminara Salvatore , Anzilotti Giulia

Background: The normal recovery of the hypothalamic–pituitary–gonadal axis after discontinuation of therapy with GNRH analogue for precocious puberty has been proven and documented in the last decades. There has been no report in the literature of patients in which a history of GNRH treatment of precocious puberty is correlated with premature ovarian failure.Objective and hypotheses: The aim of the authors is to evaluate the possibility of a co...

hrp0097p2-168 | Adrenals and HPA Axis | ESPE2023

Cushing’s Disease: an Example of Drug Shortage’s Impact in Pediatric Endocrinology.

Del Medico Giulia , Chiti Nicolo' , Stagi Stefano

Cushing’s disease (CD) is defined as hypercortisolism secondary to an adrenocorticotropin (ACTH) secreting pituitary adenoma. It is rare in the pediatric age and early diagnosis and treatment are important to prevent long-term complications. In the diagnostic workup, bilateral inferior petrosal sinus sampling (BIPSS) of ACTH after corticotropin-releasing hormone (CRH) stimulation is the gold standard in the differential diagnosis of ACTH-dependent hypercortisolism. We re...

hrp0095p1-297 | GH and IGFs | ESPE2022

rhGH therapy in a patient with homozygous IGF1R mutation

Elisa Amodeo Maria , Deodati Annalisa , Mirra Giulia , Tattesi Giulia , Cianfarani Stefano

Background: IGFR1 gene plays a crucial role in growth and glucose metabolism. IGF1R mutations account for approximately 10% of children born SGA with no catch-up growth. rhGH therapy has been reported moderately effective in stimulating growth of children with heterozygous IGF1R mutation. To date, no data are available about the efficacy of rhGH in patients with homozygous mutations.Case report: We describe a 4 years-old...

hrp0097p2-174 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

HIgh variability of phenotypic expression of the same genotype in X linked hypophosphatemic rickets (XLH)

Meneghin Alice , Mozzato Chiara , Monti Elena , Guazzarotti Laura

X-linked hypophosphataemia (XLH) is a dominant disorder caused by mutations in PHEX (located at Xp22.1), associated with rickets, lower limb deformities, pain, poor mineralization of the teeth and disproportionate short stature in children. The characteristics and severity of XLH vary between patients. Early diagnosis and specific treatment is usually decisive to improve short and long term patient outcomes. We describe the variability of phenotype in two sisters carrying the ...